Literature DB >> 1578923

An update of the results of intensive therapy in children with acute lymphoblastic leukemia.

S Pavlovsky, F Sackmann Muriel, M T Santarelli, E Svarch, E Jiménez, R Kohan, A Rosso.   

Abstract

On January 1984 a protocol for newly diagnosed children with acute lymphoblastic leukemia started in a multiinstitutional setting in Argentina, Costa Rica and Cuba. The protocol was based on the BFM 76/79 study. It consisted in 8 drug 8 weeks induction-consolidation regimen with a delayed intensification regimen followed by maintenance with 6-mercaptopurine-methotrexate and pulses with vincristine-prednisone for 36 months. CNS prophylaxis with IT therapy, age based schedule was given. Only patients with greater than 50000 WBC counts received cranial irradiation. A total of 720 patients were registered up to June 1987, 703 of them were eligible. Six hundred an twenty six (89%) of the patients achieved complete remission, 7 partial remission, 8 failed to respond and 62 (9%) had drug or disease related death before completing induction therapy. At 72 months 50% remained in complete remission, 45% and 58% of all the patients remained disease-free and alive respectively. Sites of relapse were bone marrow 21%, CNS 10%, testis 2%, combined 4% and 8% died in complete remission. No difference in response was observed among the three prognostic groups, however the disease-free survival at 72 months was 52% for good prognosis compared to 42% for intermediate and poor prognosis (P = 0.0009). This results showed a marked improvement over previous studies of our group and, that, intensive and large clinical trials can be performed in Latinamerica.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1578923

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  1 in total

1.  Malnutrition as a prognostic factor in lymphoblastic leukaemia: a multivariate analysis.

Authors:  M B Viana; M Murao; G Ramos; H M Oliveira; R I de Carvalho; M de Bastos; E A Colosimo; W S Silvestrini
Journal:  Arch Dis Child       Date:  1994-10       Impact factor: 3.791

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.